Contact
searchSearch
HMP Global
Login

ADHD Education Center

Featured

FDA building
FDA Approval
FDA Approves Centanafadine for Pediatric and Adult ADHD
07/27/2026
Maria Mantas
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
The US Food and Drug...
07/27/2026
Psych Congress Network
Viloxazine MOA Study image
Quiz
Test Your Knowledge: New Study Clarifies Multimodal Mechanism of Viloxazine in ADHD
06/12/2026
New research suggests that viloxazine has a multimodal mechanism of action. Test your understanding with this short quiz.
New research suggests that viloxazine has a multimodal mechanism of action. Test your understanding with this short quiz.
New research suggests that...
06/12/2026
Psych Congress Network
Weight scale and tape measure
Quiz
Test Your Knowledge: Retrospective Cohort Study Explores Long-Term Growth Outcomes Following Pediatric Methylphenidate Use
06/12/2026
How well do you understand the relationship between pediatric attention-deficit/hyperactivity disorder, methylphenidate use in childhood, and growth outcomes in adulthood? Test your knowledge with this short, multiple-choice quiz.
How well do you understand the relationship between pediatric attention-deficit/hyperactivity disorder, methylphenidate use in childhood, and growth outcomes in adulthood? Test your knowledge with this short, multiple-choice quiz.
How well do you understand the...
06/12/2026
Psych Congress Network
Viloxazine MOA Study image
News
New Study Clarifies Multimodal Mechanism of Viloxazine in ADHD
06/11/2026
New research further characterizes viloxazine’s pharmacologic profile, supporting a multimodal mechanism involving norepinephrine transporters and serotonin receptors.
New research further characterizes viloxazine’s pharmacologic profile, supporting a multimodal mechanism involving norepinephrine transporters and serotonin receptors.
New research further...
06/11/2026
Psych Congress Network
Weight scale and tape measure
News
Retrospective Cohort Study Explores Long-Term Growth Outcomes Following Pediatric Methylphenidate Use
06/11/2026
A retrospective cohort study examined the association between pediatric ADHD, methylphenidate exposure, and adult BMI and height outcomes. The findings suggest that ADHD—particularly when treated with methylphenidate—may be associated with...
A retrospective cohort study examined the association between pediatric ADHD, methylphenidate exposure, and adult BMI and height outcomes. The findings suggest that ADHD—particularly when treated with methylphenidate—may be associated with...
A retrospective cohort study...
06/11/2026
Psych Congress Network
Kids ride their bikes down a dirt path in a grassy field
Conference Coverage
d-ATS Shows Broad ADHD Efficacy in Pediatric Subgroups
06/06/2026
Brionna Mendoza
A poster presented at the 2026 Psych Congress Elevate reported that the dextroamphetamine transdermal system (d-ATS) was broadly effective for treating attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.
A poster presented at the 2026 Psych Congress Elevate reported that the dextroamphetamine transdermal system (d-ATS) was broadly effective for treating attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.
A poster presented at the 2026...
06/06/2026
Psych Congress Network
Girl in a classroom staring off into the distance
Quiz
Test Your Knowledge – Beyond the Stereotype: Rethinking Sex Differences in ADHD Presentation
05/12/2026
Differences in ADHD presentation between males and females may affect diagnosis and outcomes. Evaluate your understanding of key clinical distinctions with this short quiz.
Differences in ADHD presentation between males and females may affect diagnosis and outcomes. Evaluate your understanding of key clinical distinctions with this short quiz.
Differences in ADHD presentation...
05/12/2026
Psych Congress Network
A boy eating junk food while using a laptop computer
Quiz
Test Your Knowledge: The Link Between Ultra-Processed Foods and ADHD
05/12/2026
How well do you understand the emerging evidence linking ultra-processed foods and ADHD? Assess your knowledge with this brief quiz.
How well do you understand the emerging evidence linking ultra-processed foods and ADHD? Assess your knowledge with this brief quiz.
How well do you understand the...
05/12/2026
Psych Congress Network
A boy eating junk food while using a laptop computer
News
The Link Between Ultra-Processed Foods and ADHD
05/12/2026
Recent findings point to a possible link between ADHD and higher intake of ultra-processed foods.
Recent findings point to a possible link between ADHD and higher intake of ultra-processed foods.
Recent findings point to a...
05/12/2026
Psych Congress Network
Girl in a classroom staring off into the distance
Commentary
Beyond the Stereotype: Rethinking Sex Differences in ADHD Presentation
05/08/2026
This article explores how ADHD presents differently across sexes and why traditional diagnostic models may overlook symptoms in females.
This article explores how ADHD presents differently across sexes and why traditional diagnostic models may overlook symptoms in females.
This article explores how ADHD...
05/08/2026
Psych Congress Network
a girl playing a game on a tablet while lying on her stomach
Quiz
Test Your Knowledge—Digital Therapeutics: A Different Treatment Modality for ADHD
04/23/2026
How familiar are you with DTx for the treatment of attention-deficit/hyperactivity disorder? Test your knowledge with this short, multiple-choice quiz.
How familiar are you with DTx for the treatment of attention-deficit/hyperactivity disorder? Test your knowledge with this short, multiple-choice quiz.
How familiar are you with DTx...
04/23/2026
Psych Congress Network

Videos

Timothy Wilens, MD
Videos
Clinical Patterns of ADHD Comorbidities Across the Lifespan
04/01/2026
Timothy Wilens, MD
Timothy Wilens, MD, explores common patterns of attention-deficit/hyperactivity disorder (ADHD) psychiatric comorbidities throughout different developmental stages.
Timothy Wilens, MD, explores common patterns of attention-deficit/hyperactivity disorder (ADHD) psychiatric comorbidities throughout different developmental stages.
Timothy Wilens, MD, explores...
04/01/2026
Psych Congress Network
Greg Mattingly, MD
Videos
Breaking Down Treatment Barriers for Girls and Women With ADHD
07/24/2025
Greg Mattingly, MD
In this video, Psych Congress Co-Chair Greg Mattingly, MD, dives into the factors that prevent girls and women from receiving ADHD diagnoses earlier in life.
In this video, Psych Congress Co-Chair Greg Mattingly, MD, dives into the factors that prevent girls and women from receiving ADHD diagnoses earlier in life.
In this video, Psych Congress...
07/24/2025
Psych Congress Network
Sarah Slabaugh
Videos
Assessing Shame-Based Family Dynamics When Treating Children With ADHD
06/19/2025
Sarah Slabaugh, DO
Filmed ahead of her 2025 Psych Congress Elevate session, Sarah Slabaugh, DO, offers practical insights on identifying dysfunctional family patterns that may impact the presentation of ADHD symptoms in child and adolescent patients.
Filmed ahead of her 2025 Psych Congress Elevate session, Sarah Slabaugh, DO, offers practical insights on identifying dysfunctional family patterns that may impact the presentation of ADHD symptoms in child and adolescent patients.
Filmed ahead of her 2025 Psych...
06/19/2025
Psych Congress Network
Timothy Wilens, MD
Videos
Managing Life Transitions in ADHD: Why Early Preparation is Critical
09/18/2024
Timothy Wilens, MD
Timothy Wilens, MD, provides practical clinical guidance for supporting patients with ADHD through life transitions.
Timothy Wilens, MD, provides practical clinical guidance for supporting patients with ADHD through life transitions.
Timothy Wilens, MD, provides...
09/18/2024
Psych Congress Network
Julie Carbray, PhD, APRN
Videos
Screening Tools for Adult and Pediatric ADHD
08/22/2024
Julie A. Carbray, PhD, APRN
Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, provides a quick overview of some of the most widely accessible screening tools for pediatric and adult attention-deficit/hyperactivity disorder.  
Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, provides a quick overview of some of the most widely accessible screening tools for pediatric and adult attention-deficit/hyperactivity disorder.  
Julie Carbray, PhD, FPMHNP-BC,...
08/22/2024
Psych Congress Network
Drs Mattingly, Price, Amann Part 3
Videos
Navigating ADHD Care Forward: The Future of ADHD
01/15/2024
In this roundtable discussion featuring a panel of experts, Dr Gregory Mattingly, Dr Richard Price, and Dr Birgit Amann focus on the evolving future of the ADHD landscape and address current unmet needs in ADHD treatment for both adult and...
In this roundtable discussion featuring a panel of experts, Dr Gregory Mattingly, Dr Richard Price, and Dr Birgit Amann focus on the evolving future of the ADHD landscape and address current unmet needs in ADHD treatment for both adult and...
In this roundtable discussion...
01/15/2024
Psych Congress Network
Drs Mattingly, Price, Amann Part 1
Videos
ADHD Unmasked: Current ADHD Treatment Landscape
01/15/2024
In this roundtable discussion featuring a panel of experts, Dr Gregory Mattingly, Dr Richard Price, and Dr Birgit Amann delve into the evolving landscape of ADHD treatment. The panelists discuss current treatment options, including...
In this roundtable discussion featuring a panel of experts, Dr Gregory Mattingly, Dr Richard Price, and Dr Birgit Amann delve into the evolving landscape of ADHD treatment. The panelists discuss current treatment options, including...
In this roundtable discussion...
01/15/2024
Psych Congress Network
Drs Mattingly, Price, Amann Part 2
Videos
Real-World Data Deep Dive: Viloxazine ER Compared With Atomoxetine for ADHD Study
12/12/2023
In this roundtable discussion featuring a panel of experts, Dr Gregory Mattingly, Dr Richard Price, and Dr Birgit Amann explore key findings from the real-world study comparing viloxazine ER with atomoxetine for ADHD treatment in adult and...
In this roundtable discussion featuring a panel of experts, Dr Gregory Mattingly, Dr Richard Price, and Dr Birgit Amann explore key findings from the real-world study comparing viloxazine ER with atomoxetine for ADHD treatment in adult and...
In this roundtable discussion...
12/12/2023
Psych Congress Network
Greg Mattingly, MD, and Elizabeth Judd, NP, MHS
Videos
How to Incorporate Non-Stimulants Into ADHD Treatment Plans
06/05/2023
Greg Mattingly, MD, and Elizabeth Judd, NP, MHS, discuss how clinicians can incorporate non-stimulant medication into their ADHD treatment plans.
Greg Mattingly, MD, and Elizabeth Judd, NP, MHS, discuss how clinicians can incorporate non-stimulant medication into their ADHD treatment plans.
Greg Mattingly, MD, and...
06/05/2023
Psych Congress Network
Manpreet Singh
Videos
Pediatric ADHD: Proper Diagnosis, Stimulant Therapy
12/16/2021
Manpreet Singh, MD, MS, discusses introducing stimulant therapy for ADHD management, differentiating pediatric ADHD from mood disorders, and gender or ethnic bias during diagnosis.
Manpreet Singh, MD, MS, discusses introducing stimulant therapy for ADHD management, differentiating pediatric ADHD from mood disorders, and gender or ethnic bias during diagnosis.
Manpreet Singh, MD, MS,...
12/16/2021
Psych Congress Network
James Greenblatt, MD
Videos
Incorporating Integrative Approaches Into Psychiatric Care
08/05/2026
James Greenblatt, MD
James Greenblatt, MD, discusses where lifestyle, nutritional, and functional medicine strategies may help address gaps in conventional psychiatric care.
James Greenblatt, MD, discusses where lifestyle, nutritional, and functional medicine strategies may help address gaps in conventional psychiatric care.
James Greenblatt, MD, discusses...
08/05/2026
Psych Congress Network
Craig Chepke and Kevin Williams
Major Depressive Disorder Insights
Aligning Patient Goals With Novel Mechanisms in MDD Anhedonia Treatment
07/28/2026
Craig Chepke, MD, DFAPA; Kevin Williams, MS, MPAS, PA-C
Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C, discuss how clinicians can align major depressive disorder (MDD) treatment goals with patients’ lived experience of anhedonia.
Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C, discuss how clinicians can align major depressive disorder (MDD) treatment goals with patients’ lived experience of anhedonia.
Craig Chepke, MD, DFAPA, and...
07/28/2026
Psych Congress Network
Arwen Podesta, MD, DFAPA, DFASAM
Videos
Improving Alcohol Use Disorder Care With Pharmacologic Treatment
07/24/2026
Arwen Podesta, MD
In this conversation with PCN, Arwen Podesta, MD, DFAPA, DFASAM, discusses how medication-assisted therapy (MAT) may improve patient outcomes in alcohol use disorder (AUD).
In this conversation with PCN, Arwen Podesta, MD, DFAPA, DFASAM, discusses how medication-assisted therapy (MAT) may improve patient outcomes in alcohol use disorder (AUD).
In this conversation with PCN,...
07/24/2026
Psych Congress Network
Jill Harkavy-Friedman, PhD
Videos
Taking a Comprehensive Approach to Suicide Risk Assessment in Clinical Practice
07/20/2026
Jill Harkavy-Friedman, PhD
Jill Harkavy-Friedman, PhD, walks clinicians through what a comprehensive assessment of suicide risk looks like in clinical practice.
Jill Harkavy-Friedman, PhD, walks clinicians through what a comprehensive assessment of suicide risk looks like in clinical practice.
Jill Harkavy-Friedman, PhD,...
07/20/2026
Psych Congress Network
Rakesh Jain, MD, MPH
Videos
The Sleep Disorder Missteps Clinicians Can Learn From
07/16/2026
Rakesh Jain, MD, MPH, RD
Rakesh Jain, MD, MPH, Co-Chair, Psych Congress discusses why sleep complaints in psychiatric practice warrant direct evaluation rather than dismissal as secondary symptoms.
Rakesh Jain, MD, MPH, Co-Chair, Psych Congress discusses why sleep complaints in psychiatric practice warrant direct evaluation rather than dismissal as secondary symptoms.
Rakesh Jain, MD, MPH, Co-Chair,...
07/16/2026
Psych Congress Network
Kristian Dambrino, DNP, PMHNP-BC
Videos
Knowing When to Initiate Treatment for TD
07/07/2026
Kristian Dambrino, DNP, PMHNP, MSN
Psych Congress Elevate Co-Chair Kristian Dambrino, DNP, PMHNP-BC, discusses practical considerations for pinpointing whether and when to begin targeted treatment for tardive dyskinesia (TD).
Psych Congress Elevate Co-Chair Kristian Dambrino, DNP, PMHNP-BC, discusses practical considerations for pinpointing whether and when to begin targeted treatment for tardive dyskinesia (TD).
Psych Congress Elevate Co-Chair...
07/07/2026
Psych Congress Network
Kristian Dambrino, DNP, PMHNP-BC
Videos
Knowing When to Initiate Treatment for TD
07/07/2026
Kristian Dambrino, DNP, PMHNP, MSN
Psych Congress Elevate Co-Chair Kristian Dambrino, DNP, PMHNP-BC, discusses practical considerations for pinpointing whether and when to begin targeted treatment for tardive dyskinesia (TD).
Psych Congress Elevate Co-Chair Kristian Dambrino, DNP, PMHNP-BC, discusses practical considerations for pinpointing whether and when to begin targeted treatment for tardive dyskinesia (TD).
Psych Congress Elevate Co-Chair...
07/07/2026
Psych Congress Network
Craig Chepke and Kevin Williams
Major Depressive Disorder Insights
Anhedonia in MDD: What to Ask When Visit Time Is Short
07/07/2026
Craig Chepke, MD, DFAPA; Kevin Williams, MS, MPAS, PA-C
Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C, discuss how busy outpatient clinicians can effectively screen for anhedonia in major depressive disorder.
Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C, discuss how busy outpatient clinicians can effectively screen for anhedonia in major depressive disorder.
Craig Chepke, MD, DFAPA, and...
07/07/2026
Psych Congress Network
Jain, Mattingly, and Raison
Rapid Reaction
Rapid Reactions: Psych Congress Faculty Respond to HHS Deprescribing Initiative
05/12/2026
Rakesh Jain, MD, MPH, RD; Greg Mattingly, MD; Charles L. Raison, MD
Psych Congress faculty members share their expert perspectives on the HHS deprescribing action plan and Dear Colleague letter.
Psych Congress faculty members share their expert perspectives on the HHS deprescribing action plan and Dear Colleague letter.
Psych Congress faculty members...
05/12/2026
Psych Congress Network
Craig Chepke, MD, DFAPA
Videos
Treating Beyond AIMS Scores: Tracking Functional Outcomes in Tardive Dyskinesia
05/12/2026
Craig Chepke, MD, DFAPA
In this video, Craig Chepke, MD, DFAPA, Chief Medical Officer, Psych Congress, discusses the pitfalls of evaluating tardive dyskinesia (TD) treatment progress by an Abnormal Involuntary Movement Scale (AIMS) score alone.
In this video, Craig Chepke, MD, DFAPA, Chief Medical Officer, Psych Congress, discusses the pitfalls of evaluating tardive dyskinesia (TD) treatment progress by an Abnormal Involuntary Movement Scale (AIMS) score alone.
In this video, Craig Chepke, MD,...
05/12/2026
Psych Congress Network

News Articles

FDA building
FDA Approval
FDA Approves Centanafadine for Pediatric and Adult ADHD
07/27/2026
Maria Mantas
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
The US Food and Drug...
07/27/2026
Psych Congress Network
Viloxazine MOA Study image
News
New Study Clarifies Multimodal Mechanism of Viloxazine in ADHD
06/11/2026
New research further characterizes viloxazine’s pharmacologic profile, supporting a multimodal mechanism involving norepinephrine transporters and serotonin receptors.
New research further characterizes viloxazine’s pharmacologic profile, supporting a multimodal mechanism involving norepinephrine transporters and serotonin receptors.
New research further...
06/11/2026
Psych Congress Network
Weight scale and tape measure
News
Retrospective Cohort Study Explores Long-Term Growth Outcomes Following Pediatric Methylphenidate Use
06/11/2026
A retrospective cohort study examined the association between pediatric ADHD, methylphenidate exposure, and adult BMI and height outcomes. The findings suggest that ADHD—particularly when treated with methylphenidate—may be associated with...
A retrospective cohort study examined the association between pediatric ADHD, methylphenidate exposure, and adult BMI and height outcomes. The findings suggest that ADHD—particularly when treated with methylphenidate—may be associated with...
A retrospective cohort study...
06/11/2026
Psych Congress Network
A boy eating junk food while using a laptop computer
News
The Link Between Ultra-Processed Foods and ADHD
05/12/2026
Recent findings point to a possible link between ADHD and higher intake of ultra-processed foods.
Recent findings point to a possible link between ADHD and higher intake of ultra-processed foods.
Recent findings point to a...
05/12/2026
Psych Congress Network
A boy's hand holding a pill that says ADHD
News
Open-Label Extension Trial Supports Long-Term Use of Viloxazine ER in Children and Adolescents
04/13/2026
A phase 3 open-label extension trial found viloxazine ER to be safe and effective for the long-term treatment of pediatric ADHD.
A phase 3 open-label extension trial found viloxazine ER to be safe and effective for the long-term treatment of pediatric ADHD.
A phase 3 open-label extension...
04/13/2026
Psych Congress Network
A teddy bear against a blue background wearing a mask and stethoscope.
News

ADHD Incidence Trends Accelerated After DSM-5 Changes and COVID-19 Disruptions
04/10/2026
Brionna Mendoza
Attention-deficit/hyperactivity disorder (ADHD) diagnosis rates in people younger than 30 years in British Columbia, Canada, rose steadily from 2003 to 2023 and appeared to accelerate after both DSM-5 implementation and the COVID-19 pandemic.
Attention-deficit/hyperactivity disorder (ADHD) diagnosis rates in people younger than 30 years in British Columbia, Canada, rose steadily from 2003 to 2023 and appeared to accelerate after both DSM-5 implementation and the COVID-19 pandemic.
Attention-deficit/hyperactivity...
04/10/2026
Psych Congress Network
News
Co-occurring ADHD Associated With Poorer Health Outcomes in Adults With Autism on Medicaid
02/02/2026
Grace Taylor, MS, MA
A large US Medicaid study finds that co-occurring attention-deficit/hyperactivity disorder (ADHD) is common among adults with autism and is linked to higher rates of substance use, cardiovascular conditions, and injury, while ADHD medication...
A large US Medicaid study finds that co-occurring attention-deficit/hyperactivity disorder (ADHD) is common among adults with autism and is linked to higher rates of substance use, cardiovascular conditions, and injury, while ADHD medication...
A large US Medicaid study finds...
02/02/2026
First Report Managed Care
A young boy sits at a desk in a classroom
News
Higher Screen Time Tied to ADHD Symptoms, Altered Brain Structure in Children
12/03/2025
Brionna Mendoza
Higher digital screen time in preadolescent children is associated with worsening attention-deficit/hyperactivity disorder (ADHD) symptoms and measurable alterations in brain structure.
Higher digital screen time in preadolescent children is associated with worsening attention-deficit/hyperactivity disorder (ADHD) symptoms and measurable alterations in brain structure.
Higher digital screen time in...
12/03/2025
Psych Congress Network
stethoscope, pills, and a brain
News
Stimulant Treatment for ADHD Associated With Psychosis and BD
09/25/2025
Maria Mantas
Stimulant use for the treatment of attention-deficit/hyperactivity disorder (ADHD) was associated with higher occurrence of psychotic symptoms, psychotic disorders, and bipolar disorder (BD), according to a systematic review.
Stimulant use for the treatment of attention-deficit/hyperactivity disorder (ADHD) was associated with higher occurrence of psychotic symptoms, psychotic disorders, and bipolar disorder (BD), according to a systematic review.
Stimulant use for the treatment...
09/25/2025
Psych Congress Network
An orange prescription container with generic pills spilling out in front of it
News
Early ADHD Drug Treatment Linked With Reduced Risk of Suicide, Substance Misuse, and Other Adverse Outcomes
08/27/2025
Jolynn Tumolo
Patients with attention-deficit/hyperactivity disorder (ADHD) who began drug treatment within 3 months of diagnosis had significantly reduced rates of suicidal behaviors, substance misuse, traffic accidents, and criminality.
Patients with attention-deficit/hyperactivity disorder (ADHD) who began drug treatment within 3 months of diagnosis had significantly reduced rates of suicidal behaviors, substance misuse, traffic accidents, and criminality.
Patients with...
08/27/2025
Psych Congress Network
US FDA sign
News
FDA Approves Oveporexton for Adults With Narcolepsy Type 1
08/06/2026
Brionna Mendoza
The US FDA has approved oveporexton (ORZEYFUL), a first-in-class orexin treatment for narcolepsy type 1 (NT1) in adults.
The US FDA has approved oveporexton (ORZEYFUL), a first-in-class orexin treatment for narcolepsy type 1 (NT1) in adults.
The US FDA has approved...
08/06/2026
Psych Congress Network
FDA building
FDA Approval
FDA Approves Centanafadine for Pediatric and Adult ADHD
07/27/2026
Maria Mantas
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
The US Food and Drug...
07/27/2026
Psych Congress Network
illustration of a brain
Research Summary
Repeated Low-Dose Oral Esketamine Did Not Increase BDNF in Treatment-Resistant Depression
07/21/2026
Maria Mantas
Patients with TRD receiving repeated, low-dose oral esketamine did not experience greater increases in serum BDNF than those receiving placebo, according to study findings.
Patients with TRD receiving repeated, low-dose oral esketamine did not experience greater increases in serum BDNF than those receiving placebo, according to study findings.
Patients with TRD receiving...
07/21/2026
Psych Congress Network
FDA approval stamp
FDA Alerts
FDA Accepts NDA for AXS-12 in Cataplexy Associated With Narcolepsy
07/16/2026
Maria Mantas
The US Food and Drug Administration (FDA) accepted Axsome Therapeutics’ New Drug Application (NDA) for AXS-12 (reboxetine) for cataplexy in narcolepsy.
The US Food and Drug Administration (FDA) accepted Axsome Therapeutics’ New Drug Application (NDA) for AXS-12 (reboxetine) for cataplexy in narcolepsy.
The US Food and Drug...
07/16/2026
Psych Congress Network
Rakesh Jain, MD, MPH
Rapid Reaction
Rapid Reactions: Eli Lilly Acquisition Highlights Momentum in Psychedelics for Mental Health
07/16/2026
Rakesh Jain, MD, MPH, RD; Maria Mantas
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Rakesh Jain, MD, MPH, responds...
07/16/2026
Psych Congress Network
a stethoscope, pills, and brain
Research Summary
Biobehavioral Markers May Improve Antidepressant Response in Major Depressive Disorder
07/16/2026
Maria Mantas
Patients with MDD and favorable biobehavioral markers for sertraline and/or bupropion experienced higher antidepressant response rates than those with negative markers for both drugs.
Patients with MDD and favorable biobehavioral markers for sertraline and/or bupropion experienced higher antidepressant response rates than those with negative markers for both drugs.
Patients with MDD and favorable...
07/16/2026
Psych Congress Network
an illustration of a man sitting on the ground holding his head with his profile and brain in the background
Research Summary
iTBS Offers Short-Term Improvement in Major Depressive Disorder
07/10/2026
Brionna Mendoza
A randomized clinical trial found that 10 once-daily sessions of iTBS produced short-term improvement compared to sham in clinician-rated depressive symptoms among adults with recurrent major depressive disorder (MDD).
A randomized clinical trial found that 10 once-daily sessions of iTBS produced short-term improvement compared to sham in clinician-rated depressive symptoms among adults with recurrent major depressive disorder (MDD).
A randomized clinical trial...
07/10/2026
Psych Congress Network
pills spilling out of a tipped over pill bottle
News
US Veterans Study Links SGLT2 Inhibitors to Lower Dementia Risk in Older Adults With Psychiatric Disorders
07/01/2026
Maria Mantas
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders. 
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders. 
Sodium-glucose cotransporter 2...
07/01/2026
Psych Congress Network
A patient sits across from a doctor who has a clipboard and is filling out a phone
Research Summary
Single-Dose LSD Formulation Hits Primary Endpoint in Phase 3 MDD Trial
06/29/2026
Brionna Mendoza
DT120, a proprietary formulation of lysergide (LSD) for treatment of MDD, met both primary and key secondary endpoints in the phase 3 Emerge study.
DT120, a proprietary formulation of lysergide (LSD) for treatment of MDD, met both primary and key secondary endpoints in the phase 3 Emerge study.
DT120, a proprietary formulation...
06/29/2026
Psych Congress Network
a young woman lies awake in bed
News
Adolescent Insomnia and Daytime Sleepiness Linked to Depression Risk
06/25/2026
Maria Mantas
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression. 
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression. 
A 3-year longitudinal study...
06/25/2026
Psych Congress Network

Podcasts

Dr Rakesh Jain
Podcasts
Targeting Hyperactivity and Impulsivity in Adolescents: A Look at Viloxazine ER
04/17/2025
Rakesh Jain, MD, MPH, RD
Join Rakesh Jain, MD, MPH, as he explores the role of viloxazine extended-release (ER) in targeting hyperactivity and impulsivity in adolescents with ADHD.
Join Rakesh Jain, MD, MPH, as he explores the role of viloxazine extended-release (ER) in targeting hyperactivity and impulsivity in adolescents with ADHD.
Join Rakesh Jain, MD, MPH, as he...
04/17/2025
Psych Congress Network
Dr Greg Mattingly
Podcasts
Viloxazine ER: A New Era in ADHD Treatment?
04/17/2025
Greg Mattingly, MD
Join Greg Mattingly, MD, as he discusses the evolving ADHD treatment landscape, in particular extended-release viloxazine
Join Greg Mattingly, MD, as he discusses the evolving ADHD treatment landscape, in particular extended-release viloxazine
Join Greg Mattingly, MD, as he...
04/17/2025
Psych Congress Network
Greg Mattingly, MD
Podcasts
Managing Pediatric ADHD and Stress During the Holidays
12/03/2021
Greg Mattingly, MD
Greg Mattingly, MD, shares tips and advice on managing pediatric ADHD and stress through the holiday season.
Greg Mattingly, MD, shares tips and advice on managing pediatric ADHD and stress through the holiday season.
Greg Mattingly, MD, shares tips...
12/03/2021
Psych Congress Network
Psych Congress expert faculty
Podcasts
Balancing Efficacy and Tolerability in MDD Augmentation
07/28/2026
Saundra Jain, MA, PsyD, LPC; Brittany B. Albright, MD, MPH; Julie A. Carbray, PhD, APRN; Philip Gehrman, PhD; Kevin Williams, MS, MPAS, PA-C
Expert Psych Congress faculty examine how aripiprazole may be used as adjunctive treatment for MDD.
Expert Psych Congress faculty examine how aripiprazole may be used as adjunctive treatment for MDD.
Expert Psych Congress faculty...
07/28/2026
Psych Congress Network
Psych Congress faculty
Podcasts
Why Early Augmentation Conversations Matter in MDD
07/21/2026
Saundra Jain, MA, PsyD, LPC; Kevin Williams, MS, MPAS, PA-C; Brittany Albright, MD, MPH; Julie Carbray PhD, PMHNP-BC, PMHCNS-BC, APRN; Philip Gehrman, PhD
Expert Psych Congress faculty discuss how to respond when antidepressant treatment produces improvement without full remission in MDD and why augmentation should be introduced early.
Expert Psych Congress faculty discuss how to respond when antidepressant treatment produces improvement without full remission in MDD and why augmentation should be introduced early.
Expert Psych Congress faculty...
07/21/2026
Psych Congress Network
Rakesh Jain and Craig Chepke
Podcasts
Psych Congress Family & Friends Podcast, Episode 8: Beyond the Headlines: The Good, The Bad, and The Ugly of SSRIs
10/09/2025
Rakesh Jain, MD, MPH, RD; Craig Chepke, MD, DFAPA; Ragy R. Girgis, MD, MS
In this episode, Drs Rakesh Jain and Craig Chepke are joined by Dr Ragy Girgis of Columbia University to explore the small but important nuances around antidepressants, black box warnings, and violence risk in untreated psychosis.
In this episode, Drs Rakesh Jain and Craig Chepke are joined by Dr Ragy Girgis of Columbia University to explore the small but important nuances around antidepressants, black box warnings, and violence risk in untreated psychosis.
In this episode, Drs Rakesh Jain...
10/09/2025
Psych Congress Network
Craig Chepke and Rakesh Jain
Podcasts
Psych Congress Family & Friends Podcast, Episode 7: Sleep is the Foundation of Mental Health
09/12/2025
Craig Chepke, MD, DFAPA; Rakesh Jain, MD, MPH, RD
Sleep–wake disorders are clinically significant and too often overlooked in psychiatric practice. Drs. Rakesh Jain and Craig Chepke share practical strategies for recognizing and treating insomnia, hypersomnia, and obstructive sleep apnea.
Sleep–wake disorders are clinically significant and too often overlooked in psychiatric practice. Drs. Rakesh Jain and Craig Chepke share practical strategies for recognizing and treating insomnia, hypersomnia, and obstructive sleep apnea.
Sleep–wake disorders are...
09/12/2025
Psych Congress Network
Rakesh Jain and Craig Chepke
Podcasts
Psych Congress Family & Friends Podcast, Episode 6: Psychiatry Is the Specialty That Speaks for Those Without a Voice
09/08/2025
Rakesh Jain, MD, MPH, RD; Craig Chepke, MD, DFAPA
In this episode, Drs Rakesh Jain and Craig Chepke explore why fibromyalgia belongs in psychiatry’s wheelhouse and address the stigma patients face every day.
In this episode, Drs Rakesh Jain and Craig Chepke explore why fibromyalgia belongs in psychiatry’s wheelhouse and address the stigma patients face every day.
In this episode, Drs Rakesh Jain...
09/08/2025
Psych Congress Network
Craig Chepke and Rakesh Jain
Podcasts
Psych Congress Family & Friends Podcast, Episode 5: We’re Too Addicted to Our Own Good Ideas
08/25/2025
Craig Chepke, MD, DFAPA; Rakesh Jain, MD, MPH, RD
In this episode, Drs Rakesh Jain and Craig Chepke reflect on how the words we use—and the habits we form—shape the way we practice. The pair also take a fresh look at the serotonin story, talk through new ways of understanding depression, and...
In this episode, Drs Rakesh Jain and Craig Chepke reflect on how the words we use—and the habits we form—shape the way we practice. The pair also take a fresh look at the serotonin story, talk through new ways of understanding depression, and...
In this episode, Drs Rakesh Jain...
08/25/2025
Psych Congress Network
craig chepke and rakesh jain
Podcasts
Psych Congress Family & Friends Podcast, Episode 4: Every Pill is a Choice
07/25/2025
Craig Chepke, MD, DFAPA; Rakesh Jain, MD, MPH, RD
Through a positive psychiatry lens, Drs Rakesh Jain and Craig Chepke reflect on recent research, the challenges of psychiatric diagnosis, and why every treatment decision should begin with a deep understanding of the person in front of us.
Through a positive psychiatry lens, Drs Rakesh Jain and Craig Chepke reflect on recent research, the challenges of psychiatric diagnosis, and why every treatment decision should begin with a deep understanding of the person in front of us.
Through a positive psychiatry...
07/25/2025
Psych Congress Network
Dr Rakesh Jain
Podcasts
Targeting Hyperactivity and Impulsivity in Adolescents: A Look at Viloxazine ER
04/17/2025
Rakesh Jain, MD, MPH, RD
Join Rakesh Jain, MD, MPH, as he explores the role of viloxazine extended-release (ER) in targeting hyperactivity and impulsivity in adolescents with ADHD.
Join Rakesh Jain, MD, MPH, as he explores the role of viloxazine extended-release (ER) in targeting hyperactivity and impulsivity in adolescents with ADHD.
Join Rakesh Jain, MD, MPH, as he...
04/17/2025
Psych Congress Network
Dr Greg Mattingly
Podcasts
Viloxazine ER: A New Era in ADHD Treatment?
04/17/2025
Greg Mattingly, MD
Join Greg Mattingly, MD, as he discusses the evolving ADHD treatment landscape, in particular extended-release viloxazine
Join Greg Mattingly, MD, as he discusses the evolving ADHD treatment landscape, in particular extended-release viloxazine
Join Greg Mattingly, MD, as he...
04/17/2025
Psych Congress Network
Rakesh and Craig
Podcasts
Weighing the Options: Medication, Lifestyle, and the Path to Wellness
03/26/2025
Rakesh Jain, MD, MPH, RD; Craig Chepke, MD, DFAPA
In this episode, Dr Rakesh Jain and Dr Craig Chepke explore medication-induced weight gain in schizophrenia treatment and how clinicians can help patients take control of their health, mind, and body.
In this episode, Dr Rakesh Jain and Dr Craig Chepke explore medication-induced weight gain in schizophrenia treatment and how clinicians can help patients take control of their health, mind, and body.
In this episode, Dr Rakesh Jain...
03/26/2025
Psych Congress Network

Commentary

Girl in a classroom staring off into the distance
Commentary
Beyond the Stereotype: Rethinking Sex Differences in ADHD Presentation
05/08/2026
This article explores how ADHD presents differently across sexes and why traditional diagnostic models may overlook symptoms in females.
This article explores how ADHD presents differently across sexes and why traditional diagnostic models may overlook symptoms in females.
This article explores how ADHD...
05/08/2026
Psych Congress Network
a girl playing a game on a tablet while lying on her stomach
Commentary
Digital Therapeutics: A Different Treatment Modality for ADHD
04/23/2026
This article reviews the role of digital therapeutics (DTx) as an adjunctive treatment modality for ADHD, highlighting FDA‑cleared products alongside investigational interventions. It summarizes clinical evidence, safety, and use...
This article reviews the role of digital therapeutics (DTx) as an adjunctive treatment modality for ADHD, highlighting FDA‑cleared products alongside investigational interventions. It summarizes clinical evidence, safety, and use...
This article reviews the role of...
04/23/2026
Psych Congress Network
Stressed mother next to crib with baby
Commentary
Postpartum Distress in Women With ADHD: Risks, Recognition, and Evidence-Based Management
09/25/2025
This article explores the challenges of postpartum distress in women with ADHD, highlighting how symptoms and psychiatric comorbidities can intensify during pregnancy and the postpartum period. It reviews current evidence, treatment...
This article explores the challenges of postpartum distress in women with ADHD, highlighting how symptoms and psychiatric comorbidities can intensify during pregnancy and the postpartum period. It reviews current evidence, treatment...
This article explores the...
09/25/2025
Psych Congress Network
Rx pad in the shape of a cell phone with pills on the screen
Commentary
Telehealth Stimulant Prescribing and Substance Misuse Risk: What the Evidence Really Says
09/23/2025
This article reviews two large studies that evaluated whether telehealth prescribing of stimulants for ADHD increases substance misuse risk.
This article reviews two large studies that evaluated whether telehealth prescribing of stimulants for ADHD increases substance misuse risk.
This article reviews two large...
09/23/2025
Psych Congress Network
Hyper child jumps on couch while mom holds head in hands
Commentary
Beyond Symptoms: The Impact of Stigma in Families of Children With ADHD
09/19/2025
This article reviews how stigma affects families of children with ADHD—undermining help‑seeking, adherence, and well‑being—and offers clinician strategies to counter it, including destigmatizing language, brief caregiver screening, family...
This article reviews how stigma affects families of children with ADHD—undermining help‑seeking, adherence, and well‑being—and offers clinician strategies to counter it, including destigmatizing language, brief caregiver screening, family...
This article reviews how stigma...
09/19/2025
Psych Congress Network
a teenager's hand putting a bag of white pills into another teenager's hand.
Commentary
Understanding Abuse Potential Across ADHD Therapies: What Clinicians Need to Know
06/13/2025
As stimulant prescriptions for ADHD continue to rise, so does concern about their nonmedical use—particularly among adolescents and young adults.
As stimulant prescriptions for ADHD continue to rise, so does concern about their nonmedical use—particularly among adolescents and young adults.
As stimulant prescriptions for...
06/13/2025
Psych Congress Network
empty pill box on calendar with days crossed off
Commentary
Adherence and Acceptability: How Viloxazine ER Stacks Up Against Other ADHD Medications
06/13/2025
This article examines how viloxazine ER may improve adherence to ADHD treatment compared to other medications. As a non-stimulant with once-daily dosing, rapid onset, and low risk of misuse or cardiovascular issues, viloxazine ER addresses...
This article examines how viloxazine ER may improve adherence to ADHD treatment compared to other medications. As a non-stimulant with once-daily dosing, rapid onset, and low risk of misuse or cardiovascular issues, viloxazine ER addresses...
This article examines how...
06/13/2025
Psych Congress Network
A smily face button, post-it notes with A-D-H-D, and two puzzle pieces
Commentary
Combination Therapy in ADHD: When and How to Augment Treatment Safely
06/11/2025
As ADHD management becomes more nuanced, combination therapy is gaining attention as a pragmatic solution for patients who experience suboptimal outcomes or intolerable side effects on monotherapy.
As ADHD management becomes more nuanced, combination therapy is gaining attention as a pragmatic solution for patients who experience suboptimal outcomes or intolerable side effects on monotherapy.
As ADHD management becomes more...
06/11/2025
Psych Congress Network
Hand blocking small red sad face icons from large green smiling icon
Commentary
Viloxazine ER’s Impact on Comorbid Conditions: A Broader Approach to ADHD Management
06/05/2025
Managing attention-deficit/hyperactivity disorder (ADHD) often means navigating a maze of overlapping conditions—mood instability, anxiety, executive dysfunction, and more. This article explores how viloxazine ER, a non-stimulant with dual...
Managing attention-deficit/hyperactivity disorder (ADHD) often means navigating a maze of overlapping conditions—mood instability, anxiety, executive dysfunction, and more. This article explores how viloxazine ER, a non-stimulant with dual...
Managing...
06/05/2025
Psych Congress Network
Pharmacokinetics icon
Commentary
Pharmacokinetics of Viloxazine ER: What to Expect From Onset to Duration
06/05/2025
This article provides a practical breakdown of viloxazine ER’s absorption, metabolism, and elimination profiles, explaining how these features support its once-daily dosing and 24-hour symptom coverage.
This article provides a practical breakdown of viloxazine ER’s absorption, metabolism, and elimination profiles, explaining how these features support its once-daily dosing and 24-hour symptom coverage.
This article provides a...
06/05/2025
Psych Congress Network
Girl in a classroom staring off into the distance
Commentary
Beyond the Stereotype: Rethinking Sex Differences in ADHD Presentation
05/08/2026
This article explores how ADHD presents differently across sexes and why traditional diagnostic models may overlook symptoms in females.
This article explores how ADHD presents differently across sexes and why traditional diagnostic models may overlook symptoms in females.
This article explores how ADHD...
05/08/2026
Psych Congress Network
a girl playing a game on a tablet while lying on her stomach
Commentary
Digital Therapeutics: A Different Treatment Modality for ADHD
04/23/2026
This article reviews the role of digital therapeutics (DTx) as an adjunctive treatment modality for ADHD, highlighting FDA‑cleared products alongside investigational interventions. It summarizes clinical evidence, safety, and use...
This article reviews the role of digital therapeutics (DTx) as an adjunctive treatment modality for ADHD, highlighting FDA‑cleared products alongside investigational interventions. It summarizes clinical evidence, safety, and use...
This article reviews the role of...
04/23/2026
Psych Congress Network
Stressed mother next to crib with baby
Commentary
Postpartum Distress in Women With ADHD: Risks, Recognition, and Evidence-Based Management
09/25/2025
This article explores the challenges of postpartum distress in women with ADHD, highlighting how symptoms and psychiatric comorbidities can intensify during pregnancy and the postpartum period. It reviews current evidence, treatment...
This article explores the challenges of postpartum distress in women with ADHD, highlighting how symptoms and psychiatric comorbidities can intensify during pregnancy and the postpartum period. It reviews current evidence, treatment...
This article explores the...
09/25/2025
Psych Congress Network
Rx pad in the shape of a cell phone with pills on the screen
Commentary
Telehealth Stimulant Prescribing and Substance Misuse Risk: What the Evidence Really Says
09/23/2025
This article reviews two large studies that evaluated whether telehealth prescribing of stimulants for ADHD increases substance misuse risk.
This article reviews two large studies that evaluated whether telehealth prescribing of stimulants for ADHD increases substance misuse risk.
This article reviews two large...
09/23/2025
Psych Congress Network
Hyper child jumps on couch while mom holds head in hands
Commentary
Beyond Symptoms: The Impact of Stigma in Families of Children With ADHD
09/19/2025
This article reviews how stigma affects families of children with ADHD—undermining help‑seeking, adherence, and well‑being—and offers clinician strategies to counter it, including destigmatizing language, brief caregiver screening, family...
This article reviews how stigma affects families of children with ADHD—undermining help‑seeking, adherence, and well‑being—and offers clinician strategies to counter it, including destigmatizing language, brief caregiver screening, family...
This article reviews how stigma...
09/19/2025
Psych Congress Network
a teenager's hand putting a bag of white pills into another teenager's hand.
Commentary
Understanding Abuse Potential Across ADHD Therapies: What Clinicians Need to Know
06/13/2025
As stimulant prescriptions for ADHD continue to rise, so does concern about their nonmedical use—particularly among adolescents and young adults.
As stimulant prescriptions for ADHD continue to rise, so does concern about their nonmedical use—particularly among adolescents and young adults.
As stimulant prescriptions for...
06/13/2025
Psych Congress Network
empty pill box on calendar with days crossed off
Commentary
Adherence and Acceptability: How Viloxazine ER Stacks Up Against Other ADHD Medications
06/13/2025
This article examines how viloxazine ER may improve adherence to ADHD treatment compared to other medications. As a non-stimulant with once-daily dosing, rapid onset, and low risk of misuse or cardiovascular issues, viloxazine ER addresses...
This article examines how viloxazine ER may improve adherence to ADHD treatment compared to other medications. As a non-stimulant with once-daily dosing, rapid onset, and low risk of misuse or cardiovascular issues, viloxazine ER addresses...
This article examines how...
06/13/2025
Psych Congress Network
A smily face button, post-it notes with A-D-H-D, and two puzzle pieces
Commentary
Combination Therapy in ADHD: When and How to Augment Treatment Safely
06/11/2025
As ADHD management becomes more nuanced, combination therapy is gaining attention as a pragmatic solution for patients who experience suboptimal outcomes or intolerable side effects on monotherapy.
As ADHD management becomes more nuanced, combination therapy is gaining attention as a pragmatic solution for patients who experience suboptimal outcomes or intolerable side effects on monotherapy.
As ADHD management becomes more...
06/11/2025
Psych Congress Network
Hand blocking small red sad face icons from large green smiling icon
Commentary
Viloxazine ER’s Impact on Comorbid Conditions: A Broader Approach to ADHD Management
06/05/2025
Managing attention-deficit/hyperactivity disorder (ADHD) often means navigating a maze of overlapping conditions—mood instability, anxiety, executive dysfunction, and more. This article explores how viloxazine ER, a non-stimulant with dual...
Managing attention-deficit/hyperactivity disorder (ADHD) often means navigating a maze of overlapping conditions—mood instability, anxiety, executive dysfunction, and more. This article explores how viloxazine ER, a non-stimulant with dual...
Managing...
06/05/2025
Psych Congress Network
Pharmacokinetics icon
Commentary
Pharmacokinetics of Viloxazine ER: What to Expect From Onset to Duration
06/05/2025
This article provides a practical breakdown of viloxazine ER’s absorption, metabolism, and elimination profiles, explaining how these features support its once-daily dosing and 24-hour symptom coverage.
This article provides a practical breakdown of viloxazine ER’s absorption, metabolism, and elimination profiles, explaining how these features support its once-daily dosing and 24-hour symptom coverage.
This article provides a...
06/05/2025
Psych Congress Network

Quizzes

Viloxazine MOA Study image
Quiz
Test Your Knowledge: New Study Clarifies Multimodal Mechanism of Viloxazine in ADHD
06/12/2026
New research suggests that viloxazine has a multimodal mechanism of action. Test your understanding with this short quiz.
New research suggests that viloxazine has a multimodal mechanism of action. Test your understanding with this short quiz.
New research suggests that...
06/12/2026
Psych Congress Network
Weight scale and tape measure
Quiz
Test Your Knowledge: Retrospective Cohort Study Explores Long-Term Growth Outcomes Following Pediatric Methylphenidate Use
06/12/2026
How well do you understand the relationship between pediatric attention-deficit/hyperactivity disorder, methylphenidate use in childhood, and growth outcomes in adulthood? Test your knowledge with this short, multiple-choice quiz.
How well do you understand the relationship between pediatric attention-deficit/hyperactivity disorder, methylphenidate use in childhood, and growth outcomes in adulthood? Test your knowledge with this short, multiple-choice quiz.
How well do you understand the...
06/12/2026
Psych Congress Network
Girl in a classroom staring off into the distance
Quiz
Test Your Knowledge – Beyond the Stereotype: Rethinking Sex Differences in ADHD Presentation
05/12/2026
Differences in ADHD presentation between males and females may affect diagnosis and outcomes. Evaluate your understanding of key clinical distinctions with this short quiz.
Differences in ADHD presentation between males and females may affect diagnosis and outcomes. Evaluate your understanding of key clinical distinctions with this short quiz.
Differences in ADHD presentation...
05/12/2026
Psych Congress Network
A boy eating junk food while using a laptop computer
Quiz
Test Your Knowledge: The Link Between Ultra-Processed Foods and ADHD
05/12/2026
How well do you understand the emerging evidence linking ultra-processed foods and ADHD? Assess your knowledge with this brief quiz.
How well do you understand the emerging evidence linking ultra-processed foods and ADHD? Assess your knowledge with this brief quiz.
How well do you understand the...
05/12/2026
Psych Congress Network
a girl playing a game on a tablet while lying on her stomach
Quiz
Test Your Knowledge—Digital Therapeutics: A Different Treatment Modality for ADHD
04/23/2026
How familiar are you with DTx for the treatment of attention-deficit/hyperactivity disorder? Test your knowledge with this short, multiple-choice quiz.
How familiar are you with DTx for the treatment of attention-deficit/hyperactivity disorder? Test your knowledge with this short, multiple-choice quiz.
How familiar are you with DTx...
04/23/2026
Psych Congress Network
A boy's hand holding a pill that says ADHD
Quiz
Long-Term Effects of Viloxazine ER in Treatment of Pediatric ADHD
04/23/2026
Ready to apply the data? Test your knowledge of viloxazine ER for the long-term treatment of pediatric ADHD.
Ready to apply the data? Test your knowledge of viloxazine ER for the long-term treatment of pediatric ADHD.
Ready to apply the data? Test...
04/23/2026
Psych Congress Network
blocks spelling out the word "quiz"
Quiz
Screen Time, Brain Structure, and ADHD in Children
02/12/2026
Maria Mantas
Do you remember what the research says? Test your knowledge with this quick quiz!
Do you remember what the research says? Test your knowledge with this quick quiz!
Do you remember what the...
02/12/2026
Psych Congress Network
illustration of a laptop screen displaying a test
Quiz
Stimulants and Psychosis Risk in ADHD
12/22/2025
Maria Mantas
Do you remember the findings from this systematic review?
Do you remember the findings from this systematic review?
Do you remember the findings...
12/22/2025
Psych Congress Network
A woman sleeping peacefully
Quiz
Test Your Knowledge – ADHD and Sleep: Why Non-Stimulants Might Be the Right Choice (Part 3)
10/09/2025
Sleep and ADHD intersect—see if your management playbook is up to date in 3 quick questions.
Sleep and ADHD intersect—see if your management playbook is up to date in 3 quick questions.
Sleep and ADHD intersect—see if...
10/09/2025
Psych Congress Network
Blocks that spell ADHD with pills and a stethoscope
Quiz
Test Your Knowledge – The Rise of Non-Stimulant ADHD Treatments: A Paradigm Shift?
10/08/2025
Rethink ADHD beyond stimulants—test your non-stimulant savvy with 3 quick questions.
Rethink ADHD beyond stimulants—test your non-stimulant savvy with 3 quick questions.
Rethink ADHD beyond...
10/08/2025
Psych Congress Network
Chelsie Monroe Expert Insights Quiz
Expert Insights Quiz
Distinguishing EDS From Fatigue
08/03/2026
Maria Mantas
What key characteristics can help clinicians differentiate fatigue from excessive daytime sleepiness in clinical practice?
What key characteristics can help clinicians differentiate fatigue from excessive daytime sleepiness in clinical practice?
What key characteristics can...
08/03/2026
Psych Congress Network
a printed test, pencil, and clock on a desk
Quiz
Pharmacologic Treatment for Adolescent MDD
07/23/2026
Maria Mantas
Can you recall what the APA guideline recommends? Test yourself with this quick quiz!
Can you recall what the APA guideline recommends? Test yourself with this quick quiz!
Can you recall what the APA...
07/23/2026
Psych Congress Network
Craig Chepke, MD, DFAPA
Major Depressive Disorder Insights Quiz
Evaluating Anhedonia in MDD
07/22/2026
Maria Mantas
Why should clinicians think of anhedonia in major depressive disorder (MDD) as more than simply a loss of pleasure? Test your knowledge with this quiz!
Why should clinicians think of anhedonia in major depressive disorder (MDD) as more than simply a loss of pleasure? Test your knowledge with this quiz!
Why should clinicians think of...
07/22/2026
Psych Congress Network
an illustrated laptop screen displaying a quiz
Quiz
Patient Priorities in MDD Treatment
07/13/2026
Maria Mantas
Can you recall which symptom of MDD patients most wanted to see improved by treatment? Take the quiz!
Can you recall which symptom of MDD patients most wanted to see improved by treatment? Take the quiz!
Can you recall which symptom of...
07/13/2026
Psych Congress Network
Viloxazine MOA Study image
Quiz
Test Your Knowledge: New Study Clarifies Multimodal Mechanism of Viloxazine in ADHD
06/12/2026
New research suggests that viloxazine has a multimodal mechanism of action. Test your understanding with this short quiz.
New research suggests that viloxazine has a multimodal mechanism of action. Test your understanding with this short quiz.
New research suggests that...
06/12/2026
Psych Congress Network
Weight scale and tape measure
Quiz
Test Your Knowledge: Retrospective Cohort Study Explores Long-Term Growth Outcomes Following Pediatric Methylphenidate Use
06/12/2026
How well do you understand the relationship between pediatric attention-deficit/hyperactivity disorder, methylphenidate use in childhood, and growth outcomes in adulthood? Test your knowledge with this short, multiple-choice quiz.
How well do you understand the relationship between pediatric attention-deficit/hyperactivity disorder, methylphenidate use in childhood, and growth outcomes in adulthood? Test your knowledge with this short, multiple-choice quiz.
How well do you understand the...
06/12/2026
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
Psilocybin Outcomes for MDD
06/11/2026
Brionna Mendoza
Test your knowledge of recent research with this quiz!
Test your knowledge of recent research with this quiz!
Test your knowledge of recent...
06/11/2026
Psych Congress Network
Desiree Matthews, PMHNP-BC
Quiz
Drug-Drug Considerations in TD Treatment
06/10/2026
Maria Mantas
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews,...
06/10/2026
Psych Congress Network
Desiree Matthews, PMHNP-BC
Quiz
Drug-Drug Considerations in TD Treatment
06/10/2026
Maria Mantas
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews,...
06/10/2026
Psych Congress Network
Girl in a classroom staring off into the distance
Quiz
Test Your Knowledge – Beyond the Stereotype: Rethinking Sex Differences in ADHD Presentation
05/12/2026
Differences in ADHD presentation between males and females may affect diagnosis and outcomes. Evaluate your understanding of key clinical distinctions with this short quiz.
Differences in ADHD presentation between males and females may affect diagnosis and outcomes. Evaluate your understanding of key clinical distinctions with this short quiz.
Differences in ADHD presentation...
05/12/2026
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Insights
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Desiree Matthews, PHMNP-BC; Amber Hoberg, MSN, APRN, PMHNP-BC
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use